Dynamics of HER2 status following neoadjuvant systemic therapy in breast cancer: a large single-center cohort analysis
Katarzyna Pogoda, Magdalena Czopowicz, Agata Bak, Wojciech Olszewski, Michal Czopowicz, Monika Durzynska, Dorota Najmrocka, Paulina Halasa, Anna Borowiec, Zbigniew Nowecki, Anna Niwinska · 2026
Read Dynamics of HER2 status following neoadjuvant systemic therapy in breast cancer: a large single-center cohort analysis by Katarzyna Pogoda, Magdalena Czopowicz, Agata Bak, Wojciech Olszewski, Michal Czopowicz, Monika Durzynska, Dorota Najmrocka, Paulina Halasa, Anna Borowiec, Zbigniew Nowecki, Anna Niwinska (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13311251.txt.
Description
Katarzyna Pogoda and co-authors analyze the 2026 cohort on how HER2 status shifts in breast cancer after drug treatment given before surgery. Such shifts can change which follow-up drugs make sense.
The team compared tumor samples before and after treatment in 736 patients treated from 2019 to 2024. HER2 class changed in 34.2 percent of patients, and drops in HER2 level were more common than rises. New HER2-positive status after treatment was rare. Knowing how often the marker moves helps doctors decide when retesting the leftover tumor is worth doing. That timing question matters for drug choice after surgery.
Catalog record
| CREATOR | Katarzyna Pogoda, Magdalena Czopowicz, Agata Bak, Wojciech Olszewski, Michal Czopowicz, Monika Durzynska, Dorota Najmrocka, Paulina Halasa, Anna Borowiec, Zbigniew Nowecki, Anna Niwinska |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 51921 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |